| Literature DB >> 32670064 |
Xing Zhai1, Xi Wang2, Li Wang1, Linlin Xiu3, Weilu Wang3, Xiaohan Pang3.
Abstract
INTRODUCTION: The fundamental theory of traditional Chinese medicine (TCM) implies that when different diseases have the same pathogen, the syndromes of these individual diseases will be the same. "Treating different diseases with the same method" is a TCM principle suggesting that when different diseases have similar pathological changes during different stages of their development, the same method of treatment can be applied. Our study aims to analyze the concept "treating different diseases with the same method" from a molecular perspective, in order to clarify its biological basis and to objectively standardize future TCM syndrome research.Entities:
Keywords: TCMIP v2.0; complex network; information extraction; traditional Chinese medicine; treating different diseases with the same method
Year: 2020 PMID: 32670064 PMCID: PMC7332878 DOI: 10.3389/fphar.2020.00946
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Flow chart of network decomposition method.
Figure 2Symmap query interface.
Figure 3Gene entity recognition.
Figure 4Schematic diagram of combination method.
Key words of Qi deficiency and blood stasis syndrome of coronary heart disease.
| TCM symptoms | 胸痛, 胸闷, 气短,心悸, 乏力, 畏寒/肢冷, 自汗, 不寐, 舌淡紫, 偏瘫, 瘀斑, 头晕目眩 |
|---|---|
| Symptoms of modern medicine | Chest pain, chest heaviness, respiratory abnormality, palpitation, lassitude, typhoid fever/monoparesis/chills, sweating, insomnia, tongue disorder, hemiplegia, ecchymoses, dizziness |
Key words of Qi deficiency and blood stasis syndrome of stroke.
| TCM symptoms | 头晕目眩, 头痛, 易怒, 肢体麻木, 痰多, 气短, 乏力, 自汗, 便秘, 口干口渴, 舌质红, 舌质暗, 半身不遂, 口舌歪斜, 面色淡白, 瘀斑 |
|---|---|
| Symptoms of modern medicine | Dizziness, headache, irritability, numbness of extremity, sputum, respiratory abnormality, lassitude, perspiration, constipation, xerostomia, glossitis, tongue disorder, hemiplegia, stroke, ecchymoses |
Figure 5Gene network of (left) Qi deficiency and blood stasis in coronary heart disease and (right) Qi deficiency and blood stasis in stroke.
Figure 6Gene sub network divisions, (left) Qi deficiency and blood stasis in CHD and (right) Qi deficiency and blood stasis in stroke.
Top rated genes GW values in Qi deficiency and blood stasis of coronary heart disease.
| Id | Gene | Degree | Closeness | Betweeness | Hub | CMI | ZSW | GW |
|---|---|---|---|---|---|---|---|---|
| 1 | CHRNA4 | 1 | 1 | 0.29 | 1 | 1.29 | 1 | 2.29 |
| 2 | BDNF | 0.8 | 0.92 | 0.29 | 0.5 | 0.752174 | 1 | 1.75 |
| 3 | CHRNB4 | 0.6 | 0.69 | 0 | 0.7 | 0.7 | 1 | 1.70 |
| 4 | CHRNA5 | 0.5 | 0.62 | 0 | 0.64 | 0.64 | 1 | 1.64 |
| 5 | CHRNB3 | 0.5 | 0.62 | 0 | 0.62 | 0.62 | 1 | 1.62 |
| 6 | CHRNA6 | 0.4 | 0.62 | 0 | 0.54 | 0.54 | 1 | 1.54 |
| 7 | COMT | 0.5 | 0.77 | 0.14 | 0.44 | 0.530909 | 1 | 1.53 |
| 8 | CHRNA3 | 0.5 | 0.62 | 0 | 0.52 | 0.52 | 1 | 1.52 |
| 9 | CHRNB2 | 0.4 | 0.62 | 0 | 0.5 | 0.5 | 1 | 1.5 |
| 10 | MAOA | 0.4 | 0.77 | 0.14 | 0.38 | 0.452727 | 1 | 1.45 |
Top rated genes GW values in Qi deficiency and blood stasis of stroke.
| Id | Gene | Degree | Closeness | Betweeness | Hub | CMI | ZSW | GW |
|---|---|---|---|---|---|---|---|---|
| 1 | CXCR4 | 1 | 0.99 | 0.91 | 0.78 | 1.70 | 0.88 | 2.58 |
| 2 | CXCL13 | 0.92 | 0.94 | 0.65 | 0.88 | 1.52 | 0.88 | 2.40 |
| 3 | CCR7 | 0.85 | 0.88 | 0.27 | 1 | 1.06 | 0.88 | 1.94 |
| 4 | CCL2 | 0.69 | 0.87 | 0.4 | 0.83 | 1.26 | 0.63 | 1.89 |
| 5 | CXCL1 | 0.77 | 0.75 | 0.05 | 1.01 | 0.91 | 0.88 | 1.79 |
| 6 | CCR4 | 0.62 | 0.87 | 0.16 | 0.93 | 0.85 | 0.88 | 1.73 |
| 7 | CXCL9 | 0.62 | 0.75 | 0.04 | 0.88 | 0.85 | 0.88 | 1.73 |
| 8 | CCL5 | 0.69 | 0.72 | 0.08 | 0.83 | 1.04 | 0.63 | 1.67 |
| 9 | CCR2 | 0.54 | 0.72 | 0.02 | 0.87 | 0.75 | 0.88 | 1.63 |
| 10 | CCR1 | 0.54 | 0.72 | 0.01 | 0.86 | 0.55 | 1 | 1.55 |
Number of genes discovered by keyword.
| Id | Symptoms | Count |
|---|---|---|
| 1 | Dizziness | 166 |
| 2 | Constipation | 210 |
| 3 | Headache | 338 |
| 4 | Xerostomia | 87 |
| 5 | Irritability | 122 |
| 6 | Glossitis | 19 |
| 7 | Extremity Numbness | 4 |
| 8 | Hemiplegia | 65 |
| 9 | Sputums | 4 |
| 10 | Stroke | 699 |
| 11 | Respiratory Abnormality | 76 |
| 12 | Anemic | 169 |
| 13 | Lassitude | 31 |
| 14 | Ecchymoses | 24 |
| 15 | Sweating | 129 |
| 16 | Hemiplegia | 65 |
| 17 | Chest pain | 225 |
| 18 | Palpitation | 49 |
| 19 | Typhoid Fever | 82 |
| 20 | Chest Symptom Heaviness | 0 |
| 21 | Tongue Disorder | 0 |
| 22 | Insomnia | 0 |
Figure 7Gene integration steps.
Recurring genes and pathways of target syndromes.
| Channel Name | Genes | P Value |
|---|---|---|
| Inflammatory bowel disease (IBD) | IL4, IL17A, IL6, IL18, IFNG, IL13, IL12B, FOXP3, IFNGR1, IL10, IL2 | 2.49E-13 |
| Cytokine-cytokine receptor interaction | LEP, IL4, IL17A, IL6, CNTF, CLCF1, CXCR4, IL18, IFNG, IL13, CNTFR, IL12B, IL10, IFNGR1, IL2 | 3.59E-13 |
| HIF-1 signaling pathway | AKT1, EGFR, IGF1R, IL6, INS, BCL2, IFNG, IGF1, EGF, INSR, IFNGR1 | 3.07E-11 |
| Jak-STAT signaling pathway | AKT1, IL4, LEP, IL6, CNTF, IFNG, IL13, CNTFR, IL12B, IFNGR1, IL10, IL2 | 5.4E-11 |
| PI3K-Akt signaling pathway | AKT1, IL4, EGFR, IGF1R, IL6, INS, BCL2, MET, IGF1, HGF, EGF, INSR, BRCA1, IL2 | 3.34E-09 |
| Prostate cancer | AKT1, EGFR, IGF1R, AR, INS, BCL2, IGF1, EGF, CTNNB1 | 7.76E-09 |
| Pathways in cancer | AKT1, EGFR, IGF1R, AR, IL6, BMP2, CXCR4, BCL2, MET, IGF1, HGF, EGF, CTNNB1 | 2.36E-07 |
| FoxO signaling pathway | AKT1, EGFR, IGF1R, IL6, INS, IGF1, EGF, INSR, IL10 | 2.66E-07 |
| Rap1 signaling pathway | AKT1, EGFR, IGF1R, INS, MET, IGF1, HGF, EGF, INSR, CTNNB1 | 6.56E-07 |
| Chagas disease (American trypanosomiasis) | AKT1, IL6, C3, IFNG, IL12B, IFNGR1, IL10, IL2 | 9.27E-07 |
| Melanoma | AKT1, EGFR, IGF1R, MET, IGF1, HGF, EGF | 1.04E-06 |
| Tuberculosis | AKT1, IL6, C3, BCL2, IL18, IFNG, IL12B, IFNGR1, IL10 | 2.07E-06 |
| Measles | AKT1, IL4, IL6, IFNG, IL13, IL12B, IFNGR1, IL2 | 3.82E-06 |
| Proteoglycans in cancer | AKT1, EGFR, IGF1R, MET, IGF1, IGF2, IL12B, HGF, CTNNB1 | 4E-06 |
| Focal adhesion | AKT1, EGFR, IGF1R, BCL2, MET, IGF1, HGF, EGF, CTNNB1 | 4.5E-06 |
| Malaria | IL6, IL18, IFNG, MET, HGF, IL10 | 5.88E-06 |
| Ras signaling pathway | AKT1, EGFR, IGF1R, INS, MET, IGF1, HGF, EGF, INSR | 1.18E-05 |
| Leishmaniasis | IL4, C3, IFNG, IL12B, IFNGR1, IL10 | 1.41E-05 |
| African trypanosomiasis | IL6, IL18, IFNG, IL12B, IL10 | 2.45E-05 |
| Allograft rejection | IL4, IFNG, IL12B, IL10, IL2 | 3.45E-05 |
| Intestinal immune network for IgA production | IL4, IL6, CXCR4, IL10, IL2 | 6.3E-05 |
| Toxoplasmosis | AKT1, BCL2, IFNG, IL12B, IFNGR1, IL10 | 0.00018 |
| Glioma | AKT1, EGFR, IGF1R, IGF1, EGF | 0.000249 |
| AMPK signaling pathway | AKT1, LEP, IGF1R, INS, IGF1, INSR | 0.000298 |
| Adherens junction | EGFR, IGF1R, MET, INSR, CTNNB1 | 0.000448 |
| Type I diabetes mellitus | INS, IFNG, IL12B, IL2 | 0.001164 |
| Influenza A | AKT1, IL6, IL18, IFNG, IL12B, IFNGR1 | 0.001507 |
| T cell receptor signaling pathway | AKT1, IL4, IFNG, IL10, IL2 | 0.001813 |
| Endometrial cancer | AKT1, EGFR, EGF, CTNNB1 | 0.001956 |
| Ovarian steroidogenesis | IGF1R, INS, IGF1, INSR | 0.002195 |
| Legionellosis | IL6, C3, IL18, IL12B | 0.003836 |
| Signaling pathways regulating pluripotency of stem cells | AKT1, IGF1R, BMP2, IGF1, CTNNB1 | 0.004221 |
| Pertussis | IL6, C3, IL12B, IL10 | 0.006069 |
| Asthma | IL4, IL13, IL10 | 0.006078 |
| Salmonella infection | IL6, IL18, IFNG, IFNGR1 | 0.008094 |
| Non-alcoholic fatty liver disease (NAFLD) | AKT1, LEP, IL6, INS, INSR | 0.008759 |
| Rheumatoid arthritis | IL17A, IL6, IL18, IFNG | 0.009541 |
| Progesterone-mediated oocyte maturation | AKT1, IGF1R, INS, IGF1 | 0.009847 |
| Graft-versus-host disease | IL6, IFNG, IL2 | 0.013008 |
| Herpes simplex infection | IL6, C3, IFNG, IL12B, IFNGR1 | 0.0136 |
| Amoebiasis | IL6, IFNG, IL12B, IL10 | 0.01594 |
| Oocyte meiosis | IGF1R, AR, INS, IGF1 | 0.018058 |
| Aldosterone-regulated sodium reabsorption | INS, IGF1, INSR | 0.018591 |
| Insulin resistance | AKT1, IL6, INS, INSR | 0.019401 |
| Autoimmune thyroid disease | IL4, IL10, IL2 | 0.026985 |
| Non-small cell lung cancer | AKT1, EGFR, EGF | 0.027996 |
| Regulation of lipolysis in adipocytes | AKT1, INS, INSR | 0.03438 |
| mTOR signaling pathway | AKT1, INS, IGF1 | 0.035495 |
| Central carbon metabolism in cancer | AKT1, EGFR, MET | 0.040091 |
| Pancreatic cancer | AKT1, EGFR, EGF | 0.041274 |
| Fc epsilon RI signaling pathway | AKT1, IL4, IL13 | 0.041274 |
| Renal cell carcinoma | AKT1, MET, HGF | 0.04247 |
| Transcriptional misregulation in cancer | IGF1R, IL6, MET, IGF1 | 0.042499 |
| Colorectal cancer | AKT1, BCL2, CTNNB1 | 0.047383 |
| ErbB signaling pathway | AKT1, EGFR, EGF | 0.070363 |
| Choline metabolism in cancer | AKT1, EGFR, EGF | 0.088362 |
| Systemic lupus erythematosus | C3, IFNG, IL10 | 0.088362 |
| Toll-like receptor signaling pathway | AKT1, IL6, IL12B | 0.094642 |
Figure 8TCMIP v2.0 Query interface.
Figure 9PI3K-Akt signal pathways.